Dynavax Technologies (DVAX) Competitors $9.91 -0.51 (-4.91%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DVAX vs. BCRX, LGND, FOLD, CLDX, MNKD, NVAX, INVA, OPK, GERN, and RGLSShould you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Dynavax Technologies vs. BioCryst Pharmaceuticals Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Novavax Innoviva OPKO Health Geron Regulus Therapeutics BioCryst Pharmaceuticals (NASDAQ:BCRX) and Dynavax Technologies (NASDAQ:DVAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Do institutionals and insiders hold more shares of BCRX or DVAX? 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer BCRX or DVAX? BioCryst Pharmaceuticals currently has a consensus target price of $16.56, suggesting a potential upside of 66.14%. Dynavax Technologies has a consensus target price of $24.00, suggesting a potential upside of 140.65%. Given Dynavax Technologies' higher possible upside, analysts plainly believe Dynavax Technologies is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Dynavax Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, BCRX or DVAX? BioCryst Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Does the media refer more to BCRX or DVAX? In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Dynavax Technologies. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 6 mentions for Dynavax Technologies. Dynavax Technologies' average media sentiment score of 1.31 beat BioCryst Pharmaceuticals' score of 1.04 indicating that Dynavax Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dynavax Technologies 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in BCRX or DVAX? BioCryst Pharmaceuticals received 21 more outperform votes than Dynavax Technologies when rated by MarketBeat users. Likewise, 67.12% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.79% of users gave Dynavax Technologies an outperform vote. CompanyUnderperformOutperformBioCryst PharmaceuticalsOutperform Votes49867.12% Underperform Votes24432.88% Dynavax TechnologiesOutperform Votes47765.79% Underperform Votes24834.21% Which has preferable valuation and earnings, BCRX or DVAX? Dynavax Technologies has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$503.49M4.14-$226.54M-$0.26-38.33Dynavax Technologies$294.62M4.06-$6.39M-$0.52-19.18 Is BCRX or DVAX more profitable? Dynavax Technologies has a net margin of 9.85% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Dynavax Technologies' return on equity of 4.22% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-30.01% N/A -24.06% Dynavax Technologies 9.85%4.22%2.67% SummaryBioCryst Pharmaceuticals and Dynavax Technologies tied by winning 9 of the 18 factors compared between the two stocks. Get Dynavax Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DVAX vs. The Competition Export to ExcelMetricDynavax TechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$6.55B$5.40B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio55.429.1626.7419.97Price / Sales4.06258.53394.93122.22Price / CashN/A65.8538.2534.62Price / Book2.076.546.874.59Net Income-$6.39M$143.98M$3.23B$248.18M7 Day Performance6.10%4.65%5.01%2.15%1 Month Performance-4.47%9.18%12.82%16.14%1 Year Performance-12.98%-1.33%17.63%8.06% Dynavax Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DVAXDynavax Technologies4.3059 of 5 stars$9.91-4.9%$24.00+142.2%-8.5%$1.19B$294.62M55.19350Positive NewsBCRXBioCryst Pharmaceuticals4.636 of 5 stars$10.37+1.3%$16.56+59.6%+68.5%$2.17B$503.49M-17.00530Positive NewsLGNDLigand Pharmaceuticals4.428 of 5 stars$105.31+0.7%$146.14+38.8%+21.1%$2.03B$181.49M41.9680Positive NewsGap UpFOLDAmicus Therapeutics4.0573 of 5 stars$6.42-0.2%$16.22+152.7%-32.4%$1.98B$543.14M-35.67480News CoveragePositive NewsHigh Trading VolumeCLDXCelldex Therapeutics1.7905 of 5 stars$20.91+2.2%$53.90+157.8%-45.7%$1.39B$7.56M-8.14150Positive NewsMNKDMannKind2.9608 of 5 stars$4.47+2.3%$10.00+123.7%-7.2%$1.36B$297.60M63.86400NVAXNovavax3.7774 of 5 stars$7.74+15.0%$19.00+145.5%-48.1%$1.25B$1.21B-3.421,990High Trading VolumeINVAInnoviva4.3697 of 5 stars$18.63+0.3%$55.00+195.2%+16.4%$1.17B$369.84M27.00100News CoveragePositive NewsOPKOPKO Health4.4533 of 5 stars$1.33flat$2.75+106.8%+0.8%$1.05B$689.41M-7.004,200Gap UpGERNGeron4.1537 of 5 stars$1.39+9.4%$5.06+264.2%-62.7%$885.32M$116.29M-4.3470RGLSRegulus Therapeutics1.3363 of 5 stars$7.87flat$8.50+8.0%+295.5%$544.87MN/A-7.3630Analyst Forecast Related Companies and Tools Related Companies BCRX Competitors LGND Competitors FOLD Competitors CLDX Competitors MNKD Competitors NVAX Competitors INVA Competitors OPK Competitors GERN Competitors RGLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DVAX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DVAX Stock Free DVAX Stock Alerts